A Phase I/II Trial of BMS-754807 in Combination With Cetuximab (Erbitux) in Subjects With Advanced or Metastatic Solid Tumors.

Trial Profile

A Phase I/II Trial of BMS-754807 in Combination With Cetuximab (Erbitux) in Subjects With Advanced or Metastatic Solid Tumors.

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 17 Jun 2013

At a glance

  • Drugs BMS 754807 (Primary) ; Cetuximab (Primary)
  • Indications Colorectal cancer; Head and neck cancer; Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 09 Nov 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 18 Jun 2012 Actual initiation date changed from Oct 2009 to Nov 2007 as reported by ClinicalTrials.gov.
    • 29 Sep 2011 Planned end date changed from 1 Jul 2012 to 1 Jul 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top